⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15672832 | 0.81 | GRIA1 (0.35) | — | |
| SCHEMBL9665535 | 0.81 | MAPT (0.30) | — | |
| SCHEMBL805360 | 0.80 | ACACB (0.37) | — | |
| SCHEMBL3650415 | 0.79 | — | — | |
| SCHEMBL11318498 | 0.77 | — | — | |
| SCHEMBL21592509 | 0.77 | — | — | |
| SCHEMBL8277105 | 0.77 | GRIA1 (0.37) | — | |
| SCHEMBL14558217 | 0.77 | MAPT (0.35) | — | |
| SCHEMBL8393745 | 0.77 | — | — | |
| SCHEMBL3671593 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 193 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2694505-B1 | HSP90 INHIBITORS | SLOAN KETTERING INST CANCER RES (US) | 2022-04-27 | — | — | EP | claimed |
| US-10201623-B2 | HSP90-targeted cardiac imaging and therapy | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2019-02-12 | — | — | US | claimed |
| US-20160264577-A1 | HSP90 INHIBITORS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH | 2016-09-15 | — | — | US | claimed |
| US-20140088121-A1 | HSP90 Inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2014-03-27 | — | — | US | claimed |
| EP-2694505-A1 | HSP90 INHIBITORS | Sloan-kettering Institute For Cancer Research (US) | 2014-02-12 | — | — | EP | claimed |
| WO-2012138894-A1 | HSP90 INHIBITORS | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2012-10-11 | — | — | WO | claimed |
| US-12616759-B2 | Uses of labeled HSP90 inhibitors | SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 2026-05-05 | — | — | US | disclosed |
| US-20240058482-A1 | USES OF LABELED HSP90 INHIBITORS | SLOAN KETTERING INST CANCER RES (US) | 2024-02-22 | — | — | US | disclosed |
| US-20240018110-A1 | RADIOLABELED COMPOUNDS TARGETING THE PROSTATE-SPECIFIC MEMBRANE ANTIGEN | ALPHA-9 ONCOLOGY INC. (CA) | 2024-01-18 | — | — | US | disclosed |
| US-20230381180-A1 | SMALL MOLECULE MODULATORS OF KSR-BOUND MEK | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2023-11-30 | — | — | US | disclosed |
| US-20230382889-A1 | COMPOUNDS FOR INHIBITING KIF18A | VOLASTRA THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230382889-A1 | COMPOUNDS FOR INHIBITING KIF18A | VOLASTRA THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20230339964-A1 | HETEROCYCLIC COMPOUNDS AS BET INHIBITORS | NUVATION BIO INC (US) | 2023-10-26 | — | — | US | disclosed |
| US-4882342-A | CARDIOVASCULAR DISORDERS | BOEHRINGER MANNHEIM GMBH (DE) | 1989-11-21 | — | — | US | disclosed |
| US-4874756-A | CARDIOVASCULAR DISORDERS | BOEHRINGER MANNHEIM GMBH (DE) | 1989-10-17 | — | — | US | disclosed |
| US-4863945-A | CARDIOVASCULAR DISORDERS | BOEHRINGER MANNHEIM GMBH (DE) | 1989-09-05 | — | — | US | disclosed |
| US-4831032-A | CARDIOVASCULAR DISORDERS, HYPOTENSIVE, ISOTROPIC AGENTS | BOEHRINGER MANNHEIM GMBH (DE) | 1989-05-16 | — | — | US | disclosed |
| US-4810801-A | Pyrrolobenzimidazoles, pharmaceutical compositions containing them, and use of them to treat certain heart and circulatory diseases | BOEHRINGER MANNHEIM GMBH (DE) | 1989-03-07 | — | — | US | disclosed |
| US-4722929-A | Novel 2-phenyl-imidazoles and pharmaceutical compositions containing same | DR. KARL THOMAE GMBH (DE) | 1988-02-02 | — | — | US | disclosed |
| US-4710510-A | Pyrrolobenzimidazoles, pharmaceutical compositions containing them, and use of them to treat certain heart and circulatory diseases | BOEHRINGER MANNHEIM GMBH (DE) | 1987-12-01 | — | — | US | disclosed |